GREB1 tissue expression is associated with organ-confined prostate cancer

Antunes, Alberto A.; Leite, Kátia R.; Reis, Sabrina T.; Sousa-Canavez, Juliana M.; Camara-Lopes, Luiz H.; Dall'Oglio, Marcos F.; Srougi, Miguel

doi:10.1016/j.urolonc.2009.09.014

« Previous Next »Urologic Oncology: Seminars and Original Investigations
Volume 30, Issue 1 , Pages 16-20, January 2012

GREB1 tissue expression is associated with organ-confined prostate cancer☆

Alberto A. Antunes, M.D., Ph.D.
- Laboratory of Medical Investigation, LIM 55, Division of Urology, University of Sao Paulo Medical School, São Paulo, Brazil
- Corresponding author. Tel.: 55-11–30617183; fax: 55-11–30618469
Kátia R. Leite, M.D., Ph.D.
- Laboratory of Medical Investigation, LIM 55, Division of Urology, University of Sao Paulo Medical School, São Paulo, Brazil
- Genoa Biotechnology SA, Alameda Ministro Rocha Azevedo, São Paulo, Brazil
Sabrina T. Reis, Ph.D.
- Laboratory of Medical Investigation, LIM 55, Division of Urology, University of Sao Paulo Medical School, São Paulo, Brazil
Juliana M. Sousa-Canavez, Ph.D.
- Genoa Biotechnology SA, Alameda Ministro Rocha Azevedo, São Paulo, Brazil
Luiz H. Camara-Lopes, M.D., Ph.D.
- Genoa Biotechnology SA, Alameda Ministro Rocha Azevedo, São Paulo, Brazil
Marcos F. Dall'Oglio, M.D., Ph.D.
- Laboratory of Medical Investigation, LIM 55, Division of Urology, University of Sao Paulo Medical School, São Paulo, Brazil
Miguel Srougi, M.D., Ph.D.
- Laboratory of Medical Investigation, LIM 55, Division of Urology, University of Sao Paulo Medical School, São Paulo, Brazil

Received 12 August 2009; received in revised form 23 September 2009; accepted 24 September 2009. published online 30 November 2009.

Abstract

Objective

By reason of its heterogeneous behavior, it is difficult to determine the prognosis of many prostate cancer cases. Patients with the same clinicopathologic conditions may present varying clinical findings and rates of progression. We determined the role of new genes as potential molecular markers for prostate cancer prognosis.

Materials and methods

We performed a microarray analysis of two pools of patients with prostate cancer divided according to their clinicopathologic characteristics. After that, we validated these results by testing the genes with most different expressions between the two pools using the quantitative real time polymerase chain reaction method. We analyzed gene expression in 33 patients with localized prostate cancer according to prostate specific antigen (PSA), pathologic stage, Gleason score, and biochemical recurrence. For statistical analysis we used the Mann-Whitney Test.

Results

The microarray analysis revealed that 4,147 genes presented a different expression between the two pools. Among them, 3 genes, TMEFF2, GREB1, and TH1L, were at least 13-times overexpressed, and 1 gene, IGH3, which was at least 5times under-expressed in pool 1 (good prognosis) compared with pool 2 (bad prognosis), were selected for analysis. After the validation tests, GREB1 was significantly more overexpressed among patients with stage T2 compared with T3 (P = 0.020). The expressions of other 3 genes did not present significant differences according to the clinicopathological variables.